Sales of Swiss pharmaceutical company Novartis in Romania, which include both imported products and products produced through the Lek company, amounted to some 55 million euros in 2004, up nearly 40% on 2003. The growth in Novartis' Romania business was also helped by the 40% increase in sales of prescription drugs. On this market segment, Novartis Pharma Romania had a total sales volume of 17.6 million euros and a market share of 3.49%, according to a survey by market research company Cegedim. The pharmaceuticals company has a market share of 6.3% and ranks second on its market. "Novartis' growth in 2004 follows the upward trend of the entire group. With a weighted growth rate of the pharmaceutical market in Romania of 10.8% during 2001-2004, excluding non-prescription drugs, Novartis Pharma enjoyed growth of 50.9%. We intend to maintain this rate of growth in 2005," said Nicolae Voiculescu, the country manager for Novartis Romania. The group consolidated its presence on the Romanian antibiotics market last year after completing an over 9 million-euro investment in the Lek-owned factory in Targu Mures. The factory makes macrolydes (erythromycin, clarithromycin and azithromycin), which helps the group to complement its portfolio on market segment worth over 70 million euros. ZF
Pentru alte știri, analize, articole și informații din business în timp real urmărește Ziarul Financiar pe WhatsApp Channels
